Clinical Trial Update: AZD9291, an Irreversible EGFR-TKI, in Relapsed EGFR-mutated Non-small Cell Lung Cancer Patients Previously Treated With an EGFR-TKI, Coupled to Extensive Translational Studies [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update of AZD9291 (osimertinib) in relapsed EGFR-mutated non-small cell lung cancer after prior EGFR-TKI treatment, with translational st…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• AZD9291 (osimertinib)

Snippet

Sponsor: Oslo University Hospital | Conditions: Lung Cancer, Targeted Therapy | Phase 2 | Status: UNKNOWN